Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OpGen Inc OPGN

Healthcare Biotechnology
OpGen, Inc. is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company distributes molecular microbiology solutions that help guide clinicians with more information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The Company's... see more

Recent & Breaking News (OTCPK:OPGN)

OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher Healthcare

GlobeNewswire April 18, 2023

OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel

GlobeNewswire April 18, 2023

OpGen's Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND

GlobeNewswire April 5, 2023

OpGen's Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnostics

GlobeNewswire April 3, 2023

CORRECTION - OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

GlobeNewswire March 30, 2023

OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

GlobeNewswire March 29, 2023

OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2022 on March 29th at 4:30 p.m. Eastern Time

GlobeNewswire March 22, 2023

OpGen Subsidiary Ares Genetics Announces its Move to New Vienna Location and Provides Update on Business Growth

GlobeNewswire March 1, 2023

OpGen Announces Exercise of All Prefunded Warrants

GlobeNewswire February 17, 2023

OpGen subsidiary Ares Genetics announces granting of key patent in China

GlobeNewswire January 26, 2023

OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update

GlobeNewswire January 18, 2023

OpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration Project

GlobeNewswire January 17, 2023

OpGen Announces Closing of $7.5 Million Public Offering

GlobeNewswire January 11, 2023

OpGen Announces Pricing of $7.5 Million Public Offering

GlobeNewswire January 6, 2023

OpGen Announced 1-for-20 Reverse Stock Split

GlobeNewswire January 4, 2023

OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel

GlobeNewswire December 13, 2022

OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire November 10, 2022

OpGen to Provide Business Update and Financial Results for the Third Quarter 2022 on November 10th at 4:30 p.m. Eastern Standard Time

GlobeNewswire October 27, 2022

OpGen Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2022 and Provides Business Update

GlobeNewswire October 27, 2022

OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support

GlobeNewswire October 25, 2022